Oryzon Genomics (Spain)

Recent papers from Oryzon Genomics (Spain)

1. Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCRJournal of Clinical Oncology · 2026
2. 54P Real-world pCR outcomes and predictive performance of the HER2DX pCR likelihood score in early-stage HER2-positive breast cancer: A multicenter prospective subanalysisESMO Open · 2026
3. Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncologynpj Breast Cancer · 2026
4. Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)Nature Communications · 2026
5. Abstract PS4-01-07: Prospective Validation of HER2DX in Early HER2+ Breast Cancer: Operational Feasibility of Centralized Genomic Screening in the DEFINITIVE Trial. Real-Time Insights from the First 80 Screened PatientsClinical Cancer Research · 2026
6. Abstract PS5-01-23: Validation of the HER2DX Genomic Test in First-Line Advanced HER2-Positive Breast Cancer: Identifying Long-Term Responders to THPClinical Cancer Research · 2026
7. Abstract PS3-10-24: Biologic and Pathologic Correlations of the HER2DX Genomic Test in HER2+ DiseaseClinical Cancer Research · 2026
8. Abstract PS5-01-08: Development of the HER2DX Predictor of Brain Metastasis in Advanced HER2-Positive Breast Cancer Treated with First-Line THPClinical Cancer Research · 2026
9. Abstract GS1-04: Tumor infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the ECOG-ACRIN EA1181/CompassHER2 pCR trialClinical Cancer Research · 2026
10. Abstract PS4-07-06: Independent validation of TNBCDX, a 15-gene genomic risk stratification tool for early-stage triple-negative breast cancerClinical Cancer Research · 2026
11. Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxanenpj Breast Cancer · 2026
12. Meesmann Corneal Dystrophy with Epithelial Basement Membrane Abnormalities: Clinical and Genetic Analysis of Two Families with Novel and Known Mutations in KRT3 and KRT12International Journal of Molecular Sciences · 2026
13. Targeting chemoresistance: A phase II study of iadademstat (Iada) with paclitaxel (P) in extrapulmonary neuroendocrine carcinoma (epNEC) and small cell lung cancer (SCLC).Journal of Clinical Oncology · 2026
14. Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implicationsnpj Breast Cancer · 2025
15. Associations of the HER2DX Genomic Test with Biological and Pathological Features in HER2-positive Breast CancerClinical Cancer Research · 2025
16. Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumabnpj Breast Cancer · 2025
17. Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenograftsnpj Precision Oncology · 2025
18. Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenograftsnpj Precision Oncology · 2025
19. HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapyNature Communications · 2025
20. Genetic Insights into Acne, Androgenetic Alopecia, and Alopecia Areata: Implications for Mechanisms and Precision DermatologyCosmetics · 2025